

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 April 2024 (18.04.2024)



(10) International Publication Number
WO 2024/081954 A2

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/713 (2006.01)

(21) International Application Number:
PCT/US2023/076973

(22) International Filing Date:
16 October 2023 (16.10.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/416,070 14 October 2022 (14.10.2022) US

(71) Applicant: SANEGENE BIO USA INC. [US/US]; 1
Broadway, FL 14, Cambridge, Massachusetts 02142 (US).

(72) Inventors: ZHANG, Chunyang; c/o Sanegene Bio USA
Inc., 1 Broadway, FL 14, Cambridge, Massachusetts
02142 (US). GENG, Xin; c/o Sanegene Bio USA Inc., 1
Broadway, FL 14, Cambridge, Massachusetts 02142 (US).
WANG, Shiyu; c/o Sanegene Bio USA Inc., 1 Broadway,
FL 14, Cambridge, Massachusetts 02142 (US). WANG,
Weimin; c/o Sanegene Bio USA Inc., 1 Broadway, FL 14,
Cambridge, Massachusetts 02142 (US).

(74) Agent: CHEN, Chen et al.; Cooley LLP, 1299 Pennsylva-
nia Avenue, NW, Suite 700, Washington, District of Colum-
bia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SMALL INTERFERING RNA TARGETING C3 AND USES THEREOF




FIG. 5B

(57) Abstract: This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human complement C3 mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating C3 gene expression.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*